Go offline with the Player FM app!
From Antibodies To Precision Care: Building Smarter Combination Therapies For Alzheimer’s
Manage episode 517924598 series 2993661
We trace the leap from single‑target antibodies that slow decline by about 30 percent to ambitious combination strategies that attack Alzheimer’s from multiple angles. Along the way we unpack drug‑device synergies, biomarker‑guided precision, smarter trials, and the hard question of affordability.
• proof of concept for anti‑amyloid efficacy and its ceiling
• rationale for multi‑target combinations beyond amyloid and tau
• add‑on layering versus purpose‑built novel combinations
• drug‑device approaches including focused ultrasound to open the BBB
• mechanism optimization for metabolism, tolerability and penetration
• integrated care with lifestyle, metabolic targets and quality oversight
• factorial and fast‑fail trial designs to test synergy efficiently
• biomarkers for target engagement and predictive selection
• platform trials to accelerate and streamline development
• access, cost and routes to democratize effective treatment
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Chapters
1. Proof Of Concept And Its Limits (00:00:00)
2. Why Combination Therapy Is Essential (00:01:00)
3. Two Paths To Multi‑Target Treatments (00:02:20)
4. Beyond Amyloid And Tau (00:04:30)
5. Add‑Ons And Next‑Gen Layering (00:07:00)
6. Drug‑Device Synergy With Focused Ultrasound (00:09:20)
7. Mechanism Optimization: Metabolism And Side Effects (00:12:00)
8. Crossing The Blood‑Brain Barrier Smarter (00:15:00)
9. Integrated Approaches: Drugs Plus Lifestyle (00:17:20)
110 episodes
Manage episode 517924598 series 2993661
We trace the leap from single‑target antibodies that slow decline by about 30 percent to ambitious combination strategies that attack Alzheimer’s from multiple angles. Along the way we unpack drug‑device synergies, biomarker‑guided precision, smarter trials, and the hard question of affordability.
• proof of concept for anti‑amyloid efficacy and its ceiling
• rationale for multi‑target combinations beyond amyloid and tau
• add‑on layering versus purpose‑built novel combinations
• drug‑device approaches including focused ultrasound to open the BBB
• mechanism optimization for metabolism, tolerability and penetration
• integrated care with lifestyle, metabolic targets and quality oversight
• factorial and fast‑fail trial designs to test synergy efficiently
• biomarkers for target engagement and predictive selection
• platform trials to accelerate and streamline development
• access, cost and routes to democratize effective treatment
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Chapters
1. Proof Of Concept And Its Limits (00:00:00)
2. Why Combination Therapy Is Essential (00:01:00)
3. Two Paths To Multi‑Target Treatments (00:02:20)
4. Beyond Amyloid And Tau (00:04:30)
5. Add‑Ons And Next‑Gen Layering (00:07:00)
6. Drug‑Device Synergy With Focused Ultrasound (00:09:20)
7. Mechanism Optimization: Metabolism And Side Effects (00:12:00)
8. Crossing The Blood‑Brain Barrier Smarter (00:15:00)
9. Integrated Approaches: Drugs Plus Lifestyle (00:17:20)
110 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.